参考文献:
[1]ZHENG RS,ZHANG SW,ZENG HM,et al.Cancer incidence and mortality in China,2016[EB/OL].[2022-02-27].Journal of the Nationl Cancer Center.
[2]佘明金.食管鳞状细胞癌的治疗现状和进展[J].癌症进展,2022, 20(2):122-126.
[3]毛友生,高树庚,王群,等.中国食管癌临床流行特征及外科治疗概况大数据分析[J].中华肿瘤杂志,2020, 42(3):228-233.
[4]Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021;71(3):209-249.
[5]LU ZH, WANG JY, SHU YQ,et al.Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J].BMJ,2022 Apr 19;377:e068714. DOI: 10.1136/bmj-2021-068714.
[6]van HALTEREN HK,TAN A,PELLEGRINO B,et al.11ESMO 2021 breakingthroughs:practicing oncologist's perceptions on data presentation[R/OL].2021 ESMO.
[7]焦曦,鲁智豪.2021年食管癌临床治疗进展[J].肿瘤综合治疗电子杂志,2022, 8(1):61-71.